Clinical trials: MTOR
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Advanced Nonhematologic Malignancies
A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies
The purpose of this study was to evaluate the safety and to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and dosing schedules of oral TAK-228+TAK-117.
- Trial name
- NCT01899053
- Testing
- TAK-228, TAK-117
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Desmoid Tumor
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid-type fibromatosis (or desmoid tumor) represents an intermediate grade neoplasm with a striking predilection for locally invasive growth and recurrence following resection. It occurs in children as well as young adults.
- Trial name
- NCT01265030
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- MaineHealth
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable…
- Trial name
- NCT02008877
- Testing
- ganetespib, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Activated PI3K-delta Syndrome, Immunodeficiency Primary
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome
The purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin therapy in patients with activated phosphoinositide 3-kinase δ syndrome (APDS).
- Trial name
- NCT03383380
- Testing
- Rapamycin
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Fudan University
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR) inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in…
- Conditions
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure, Sars-CoV2
- Trial name
- RAPA-CARDS (NCT04482712)
- Testing
- Rapamycin
- Where
- 2 sites in United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Postmenopausal Women
Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women
It is estimated that women lose around 20-25% of bone mass during the 5-10 years period of postmenopausal transition, and menopause is considered a major risk factor for osteoporotic fragility fracture.
- Trial name
- RapaLoad (NCT06789900)
- Testing
- Everolimus (Afinitor®), Football Fitness Concept
- Where
- Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Muscle Atrophy, Age-Related Sarcopenia
Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)
As people age, muscle mass and function is lost and exercise training is an important way to reduce the effects of this and remain independent.
- Trial name
- Rapamune (NCT05414292)
- Testing
- Rapamune (sirolimus) 1Mg Tablet, Unilateral resistance exercise training
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Atherosclerosis
Leucine, mTOR and Athero
High protein low carbohydrate diets have become popular in recent years to help facilitate weight loss. It is controversial if these diets are associated with an increased risk of cardiovascular disease.
- Trial name
- HPL (NCT05470218)
- Testing
- Meal
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery
This phase II trial studies the effects of temsirolimus in treating patients with cervical cancer that cannot be cured by standard therapy.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT01026792
- Testing
- Temsirolimus, Laboratory Biomarker Analysis
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Adenocarcinoma of the Prostate
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01174199
- Testing
- vorinostat, temsirolimus, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Roswell Park Cancer Institute
Tuberous Sclerosis Complex, Epilepsy
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC).
- Trial name
- RESTOR-1 (NCT07680322)
- Testing
- AV078
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Metastatic Breast Cancer
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Post-menopausal women with hormone-receptor positive (HR+) metastatic breast cancer resistant to aromatase inhibitor (AI) therapy will be randomized to receive Fulvestrant (Faslodex) with Everolimus or Fulvestrant (Faslodex) with…
- Trial name
- PrE0102 (NCT01797120)
- Testing
- Fulvestrant, Everolimus
- Where
- 25 sites in United States
- Volunteers
- 131 people
- Sponsor
- PrECOG, LLC.
Hepatocellular Carcinoma
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
The purpose of this study is to determine the safety and efficacy of sirolimus-based immunosuppressive therapy in patients following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), with regard to HCC…
- Trial name
- NCT00355862
- Testing
- CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free), Sirolimus
- Where
- Germany
- Volunteers
- 525 people
- Sponsor
- University of Regensburg
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients
Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.
The overall objective of this project is to optimise preventive treatment of CMV infection/disease in renal transplant recipients at increased risk of CMV post-transplantation.
- Trial name
- NCT07203664
- Testing
- steroids, tacrolimus and mTOR inhibitors, steroids, tacrolimus and mycophenolic acid.
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario La Paz
Epilepsy, Tuberous Sclerosis Complex
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
The goal of this study is to learn if the study drug RAD001 can reduced the number of epileptic seizures, and can be taken safety by people who have epilepsy associated with Tuberous Sclerosis Complex.
- Trial name
- NCT01070316
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Vascular Malformations
An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations
This study is a single-arm exploratory trial conducted by Xuanwu Hospital, Capital Medical University, aiming to evaluate the efficacy and safety of everolimus monotherapy in adult patients with vascular malformations.
- Trial name
- NCT07037238
- Testing
- Everolimus 10mg daily
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xuanwu Hospital, Beijing
Kidney Transplant Infection, BK Virus Infection
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient
BK virus infection is one of the causes of renal allograft loss in the current era. Reduction of immunsuppression is the only intervention that prooved to be effective in treating of BK virus in kidney transplant recipient.
- Trial name
- ELF (NCT04542733)
- Testing
- Everolimus, reduced dose tacrolimus and Leflunomide
- Where
- Thailand
- Volunteers
- 50 people
- Sponsor
- King Chulalongkorn Memorial Hospital
Breast Cancer, PI3K/AKT/mTOR Pathway Mutation
Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.14 cases of HER2- metastatic breast cancer patients with PI3K/AKT/mTOR…
- Conditions
- Breast Cancer, PI3K/AKT/mTOR Pathway Mutation, Everolimus
- Trial name
- NCT05054166
- Testing
- No intervention, it was a retrospective study.
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Zhejiang Cancer Hospital